NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Latigo Biotherapeutics

Latigo Biotherapeutics

Private
Thousand Oaks, CaliforniaHealthcare & Life Scienceshttps://latigobio.com/

Last Round

Series B

Mar 17, 2025

Total Funding Raised

$285M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Latigo Biotherapeutics is a biotechnology company developing innovative non-opioid pain medicines that target pain at its source to provide effective, rapid-acting relief without the risk of addiction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

non-opioid pain therapeuticspain managementbiotechnologydrug discoverysmall molecule therapeuticsclinical trialsNav1.8 inhibitorsAI drug discoverynon-addictive pain reliefbiopharmaclinical-stage biotechstructure-based drug designpain technext-gen pain meds

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Latigo Biotherapeutics Comparables

Compare Latigo Biotherapeutics with similar companies based on industry and business-model similarity.

Latigo Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Centrexion Therapeutics
87%
Tafalgie Therapeutics
86%
South Rampart Pharma, Inc.
84%

Latigo Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 17, 2025
Series AFeb 14, 2024

Latigo Biotherapeutics Investors

Notable investors and investment history

Latigo Biotherapeutics investors
InvestorRounds
Westlake Village BioPartnersSeries B, Series A
Cormorant Asset ManagementSeries B
Corner VenturesSeries A
Blue Owl CapitalSeries B
Deep Track CapitalSeries B
5AM VenturesSeries B, Series A
Foresite CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors grew 31% MoM, from 4.2K to 5.5K.

  • May 16, 2026

    Web traffic grew 63% MoM (from 846 to 1.4K monthly visitors)

Latigo Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Latigo Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Latigo Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersThousand Oaks, California
Employee Range60
Year Founded2018
Last FundingMar 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.